2024
Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification
Ghosh A, Venkatraman S, Nanna M, Safford M, Colantonio L, Brown T, Pinheiro L, Peterson E, Navar A, Sterling M, Soroka O, Nahid M, Banerjee S, Goyal P. Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification. JAMA Cardiology 2024, 9: 55-62. PMID: 38055247, PMCID: PMC10701663, DOI: 10.1001/jamacardio.2023.4520.Peer-Reviewed Original ResearchConceptsLipoprotein cholesterol levelsAtherosclerotic cardiovascular diseaseCohort studyREGARDS cohortCholesterol levelsCardiovascular diseaseLow-density lipoprotein cholesterol levelsCoronary heart disease deathDensity lipoprotein cholesterol levelsRace-sex stratumHeart disease deathProspective cohort studyCohort risk equationsRisk predictionRace stratificationIncident ASCVDNonfatal strokeDisease deathsC-statisticMyocardial infarctionHigh riskRisk equationsSocial determinantsPercentage declineIncremental value
2023
Hierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease
Damluji A, Ijaz N, Chung S, Xue Q, Hasan R, Batchelor W, Orkaby A, Kochar A, Nanna M, Roth D, Walston J, Resar J, Gerstenblith G. Hierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease. JACC Advances 2023, 2: 100318. PMID: 37538136, PMCID: PMC10399211, DOI: 10.1016/j.jacadv.2023.100318.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAdverse cardiovascular eventsCognitive impairmentCardiovascular eventsCardiovascular outcomesCardiovascular riskCardiovascular diseaseIncident major adverse cardiovascular eventsOlder adultsAdverse cardiovascular outcomesIncident cardiovascular diseasePhysical frailty phenotypeCoronary artery diseaseMultiple chronic conditionsPoor health outcomesAging Trends StudyFrailty phenotypeArtery diseasePrimary outcomeGeriatric conditionsChronic conditionsNational HealthPhysical frailtyStudy populationHigh risk
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsDeprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPreventionReadmission and In-Hospital Outcomes After Transcatheter Aortic Valve Replacement in Patients With Dementia
Park DY, Sana MK, Shoura S, Hammo H, Hu JR, Forrest JK, Lowenstern A, Cleman M, Ahmad Y, Nanna MG. Readmission and In-Hospital Outcomes After Transcatheter Aortic Valve Replacement in Patients With Dementia. Cardiovascular Revascularization Medicine 2022, 46: 70-77. PMID: 35973922, PMCID: PMC10940024, DOI: 10.1016/j.carrev.2022.08.016.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAortic stenosisValve replacementSecondary diagnosisHospital adverse outcomesAcute kidney injuryIn-Hospital OutcomesNational Readmission DatabasePresence of dementiaPrevalence of dementiaProportional hazards modelDecade of ageHigher hazardIndex hospitalizationInpatient outcomesKidney injuryDefinitive treatmentPacemaker placementReadmission riskAdverse outcomesReadmissionHigher oddsDecision-making discussionsHigh risk
2020
EVALUATING THE 2018 AHA/ACC LIPID GUIDELINE PERFORMANCE TO IDENTIFY PATIENTS AT HIGH RISK FOR PREMATURE CARDIOVASCULAR DISEASE
Zeitouni M, Nanna M, Sun J, Chiswell K, Peterson E, Navar A. EVALUATING THE 2018 AHA/ACC LIPID GUIDELINE PERFORMANCE TO IDENTIFY PATIENTS AT HIGH RISK FOR PREMATURE CARDIOVASCULAR DISEASE. Journal Of The American College Of Cardiology 2020, 75: 1981. DOI: 10.1016/s0735-1097(20)32608-5.Peer-Reviewed Original Research